| Ms Mara Christine Limoncelli, PA-C | |
|
1006 W Main St, Bozeman, MT 59715-3219 | |
| (406) 414-4800 | |
| Not Available |
| Full Name | Ms Mara Christine Limoncelli |
|---|---|
| Gender | Female |
| Speciality | Physician Assistant |
| Experience | 14 Years |
| Location | 1006 W Main St, Bozeman, Montana |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1942590583 | NPI | - | NPPES |
| 500705178 | Medicaid | OR |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207N00000X | Dermatology | PA158092 (Oregon) | Secondary |
| 363A00000X | Physician Assistant | PA158092 (Oregon) | Secondary |
| 363A00000X | Physician Assistant | 104134 (Montana) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Bozeman Health Deaconess Hospital | Bozeman, MT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Bozeman Health Urgent Care | 3476879305 | 23 |
| Shannon Setzer Md Pc | 5698822989 | 4 |
News Archive
By blocking a protein, VDAC1, in the insulin-producing beta cells, it is possible to restore their normal function in case of type 2 diabetes. In preclinical experiments, the researchers behind a new study have also shown that it is possible to prevent the development of the disease.
With health care providers' desire to increase accuracy, lower costs and increase efficiency, e-prescription use in the United States is exploding. Surescripts reports that by the end of 2009, approximately 18 percent of eligible prescriptions were prescribed electronically compared with just 6.6 percent at the end of 2008. And, the number of prescriptions routed electronically jumped from 68 million in 2008 to 191 million in 2009.
86% of UK residents who tested positive for COVID-19 during lockdown did not have the specific virus symptoms (cough, and/or fever, and/or loss of taste/smell), finds a new study by UCL researchers. The authors say a more widespread testing programme is needed to catch 'silent' transmission and reduce future outbreaks.
The ACTIV-3 clinical trial, which is evaluating the safety and efficacy of investigational therapeutics for COVID-19 in hospitalized patients, has closed enrollment in two sub-studies: one examining the investigational monoclonal antibody therapy VIR-7831, and another evaluating the investigational combination monoclonal antibody therapy containing BRII-196 and BRII-198.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ms Mara Christine Limoncelli, PA-C 1006 W Main St, Bozeman, MT 59715-3219 Ph: (406) 414-4800 | Ms Mara Christine Limoncelli, PA-C 1006 W Main St, Bozeman, MT 59715-3219 Ph: (406) 414-4800 |
News Archive
By blocking a protein, VDAC1, in the insulin-producing beta cells, it is possible to restore their normal function in case of type 2 diabetes. In preclinical experiments, the researchers behind a new study have also shown that it is possible to prevent the development of the disease.
With health care providers' desire to increase accuracy, lower costs and increase efficiency, e-prescription use in the United States is exploding. Surescripts reports that by the end of 2009, approximately 18 percent of eligible prescriptions were prescribed electronically compared with just 6.6 percent at the end of 2008. And, the number of prescriptions routed electronically jumped from 68 million in 2008 to 191 million in 2009.
86% of UK residents who tested positive for COVID-19 during lockdown did not have the specific virus symptoms (cough, and/or fever, and/or loss of taste/smell), finds a new study by UCL researchers. The authors say a more widespread testing programme is needed to catch 'silent' transmission and reduce future outbreaks.
The ACTIV-3 clinical trial, which is evaluating the safety and efficacy of investigational therapeutics for COVID-19 in hospitalized patients, has closed enrollment in two sub-studies: one examining the investigational monoclonal antibody therapy VIR-7831, and another evaluating the investigational combination monoclonal antibody therapy containing BRII-196 and BRII-198.
› Verified 4 days ago